(Reuters) – Regeneron Pharmaceuticals said on Thursday its COVID-19 antibody therapy has diminished potency against the Omicron variant.
The drugmaker said the currently authorized therapy, REGEN-COV, is still active against Delta, which currently is the most prevalent variant in the U.S.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
